Focally positive margins in breast conserving surgery: Predictors, residual disease, and local recurrence

Vos, Elvira L.; Gaal, José; Verhoef, Cornelis; Brouwer, Kim M.; Deurzen, Carolien H.M. van; Koppert, Linetta B.

doi:10.1016/j.ejso.2017.06.007

Cited by 40 publications

(31 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A recent study has also raised concerns about the use of no tumor on ink as a sufficient negative margin, in that (45.7%) patients with close margins who had a re-excision had residual disease in the re-excision. This rate of residual disease was similar to patients with focally positive margins (48.7%) although not as high as the rate in patients with extensively involved margins (78.3%) [11].…”

supporting

confidence: 64%

Excision Margins in Breast Conserving Therapy

Dixon

Cartlidge

2017

Breast Cancer Manag.

View full text Add to dashboard Cite

supporting

confidence: 64%

Excision Margins in Breast Conserving Therapy

Dixon

Cartlidge

2017

Breast Cancer Manag.

View full text Add to dashboard Cite

“…However, the Dutch Breast Cancer Guidelines considers the recurrence risk for focally (≤ 4 mm) positive margins after BCT (resection followed by radiation treatment) acceptable [ 22 ]. Vos et al concluded that this focal involvement is usually caused by radial extensions (spicules) of the tumor or residual DCIS [ 30 ]. In another study, Vos et al state that omitting re-excision for focally positive margins does not impair the 5-year disease-free and 10-year overall survival rates, provided that adjuvant whole-breast irradiation is given, including a boost to the tumor bed [ 31 ].…”

Section: Discussionmentioning

confidence: 99%

Minimally invasive breast cancer excision using the breast lesion excision system under ultrasound guidance

Sanderink¹,

Strobbe

Bult

et al. 2020

Breast Cancer Res Treat

View full text Add to dashboard Cite

Purpose To assess the feasibility of completely excising small breast cancers using the automated, image-guided, single-pass radiofrequency-based breast lesion excision system (BLES) under ultrasound (US) guidance. Methods From February 2018 to July 2019, 22 patients diagnosed with invasive carcinomas ≤ 15 mm at US and mammography were enrolled in this prospective, multi-center, ethics board-approved study. Patients underwent breast MRI to verify lesion size. BLES-based excision and surgery were performed during the same procedure. Histopathology findings from the BLES procedure and surgery were compared, and total excision findings were assessed. Results Of the 22 patients, ten were excluded due to the lesion being > 15 mm and/or being multifocal at MRI, and one due to scheduling issues. The remaining 11 patients underwent BLES excision. Mean diameter of excised lesions at MRI was 11.8 mm (range 8.0–13.9 mm). BLES revealed ten (90.9%) invasive carcinomas of no special type, and one (9.1%) invasive lobular carcinoma. Histopathological results were identical for the needle biopsy, BLES, and surgical specimens for all lesions. None of the BLES excisions were adequate. Margins were usually compromised on both sides of the specimen, indicating that the excised volume was too small. Margin assessment was good for all BLES specimens. One technical complication occurred (retrieval of an empty BLES basket, specimen retrieved during subsequent surgery). Conclusions BLES allows accurate diagnosis of small invasive breast carcinomas. However, BLES cannot be considered as a therapeutic device for small invasive breast carcinomas due to not achieving adequate excision.

show abstract

“…Quand elle est possible, la chirurgie est la première approche thérapeutique en oncologie et elle reste la plus efficace. De nombreuses études montrent qu'une chirurgie ayant conduit à des berges saines (R0) 1 est le meilleur facteur pronostic dans différents types de cancers [1,2]. Pour le chirurgien oncologue, l'idée de voir en temps réel les zones tumorales (tumeur primaire, petites métastases, invasions dans les zones péritumorales, etc.)…”

Section: La Chirurgie Guidée Par La Fluorescence En Oncologieunclassified

Les anticorps, outils de choix pour la chirurgie guidée par fluorescence

2019

View full text Add to dashboard Cite

La chirurgie guidée par fluorescence se développe en clinique depuis plusieurs années. Si l’utilisation de colorants non ciblés peut être utile dans certaines pathologies, des agents de contraste spécifiques sont indispensables en oncologie. Comme le montrent les dernières études cliniques, les anticorps monoclonaux ont toutes les caractéristiques pour jouer un rôle majeur dans ce domaine d’imagerie médicale, à condition que la cible antigénique soit pertinente.

show abstract

Focally positive margins in breast conserving surgery: Predictors, residual disease, and local recurrence

Cited by 40 publications

References 49 publications

Excision Margins in Breast Conserving Therapy

Excision Margins in Breast Conserving Therapy

Minimally invasive breast cancer excision using the breast lesion excision system under ultrasound guidance

Les anticorps, outils de choix pour la chirurgie guidée par fluorescence

Contact Info

Product

Resources

About